
Myomo MYO
$ 0.69
-0.95%
Annual report 2025
added 03-09-2026
Myomo Accounts Payables 2011-2026 | MYO
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Myomo
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.51 M | 1.17 M | 570 K | 723 K | 180 K | 450 K | 427 K | 265 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.51 M | 180 K | 662 K |
Quarterly Accounts Payables Myomo
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.62 M | 2.51 M | 2.49 M | 1.17 M | 1.3 M | 1.37 M | 829 K | 1.07 M | 1.22 M | 767 K | 907 K | 570 K | 879 K | - | 1.01 M | 723 K | 624 K | 612 K | 714 K | 180 K | 180 K | 180 K | 180 K | 450 K | 450 K | 450 K | 450 K | 427 K | 427 K | 427 K | 427 K | 265 K | 265 K | 265 K | 265 K | 311 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.51 M | 180 K | 743 K |
Accounts Payables of other stocks in the Medical devices industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
2.89 M | $ 33.06 | -0.68 % | $ 1.52 B | ||
|
EDAP TMS S.A.
EDAP
|
5.71 M | $ 3.87 | 4.18 % | $ 145 M | ||
|
Establishment Labs Holdings
ESTA
|
43.1 M | $ 59.71 | 0.23 % | $ 1.77 B | ||
|
Edwards Lifesciences Corporation
EW
|
228 M | $ 83.36 | 0.83 % | $ 48.7 B | ||
|
Axonics Modulation Technologies
AXNX
|
9.07 M | - | - | $ 3.31 B | ||
|
Helius Medical Technologies
HSDT
|
531 K | $ 2.04 | -5.79 % | $ 1.24 M | ||
|
Aziyo Biologics
AZYO
|
4.79 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
2.76 M | - | -26.83 % | $ 2.62 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
82.5 M | $ 9.86 | 3.25 % | $ 759 M | ||
|
Inogen
INGN
|
20.3 M | $ 6.61 | 2.88 % | $ 176 M | ||
|
Allied Healthcare Products
AHPI
|
1.21 M | - | 3.58 % | $ 2.21 M | ||
|
IRIDEX Corporation
IRIX
|
4.5 M | $ 1.34 | 1.41 % | $ 21.6 M | ||
|
IRadimed Corporation
IRMD
|
1.82 M | $ 101.07 | -0.7 % | $ 1.29 B | ||
|
LENSAR
LNSR
|
6 M | $ 5.57 | -0.18 % | $ 64.2 M | ||
|
Conformis
CFMS
|
4.16 M | - | - | $ 16.4 M | ||
|
Delcath Systems
DCTH
|
2.66 M | $ 9.13 | -0.76 % | $ 327 M | ||
|
Medtronic PLC
MDT
|
2.45 B | $ 88.72 | 0.96 % | $ 114 B | ||
|
Dynatronics Corporation
DYNT
|
3.4 M | - | 14.99 % | $ 929 K | ||
|
Cardiovascular Systems
CSII
|
14.4 M | - | 0.15 % | $ 844 M | ||
|
Second Sight Medical Products
EYES
|
817 K | - | -0.97 % | $ 54.4 M | ||
|
Apollo Endosurgery
APEN
|
7.42 M | - | - | $ 475 M | ||
|
Orthofix Medical
OFIX
|
58.4 M | $ 11.9 | -0.25 % | $ 471 M | ||
|
Avinger
AVGR
|
777 K | - | -20.74 % | $ 369 K | ||
|
Outset Medical
OM
|
554 K | $ 3.6 | 1.98 % | $ 54.8 K | ||
|
CONMED Corporation
CNMD
|
93.6 M | $ 36.92 | -0.43 % | $ 1.15 B | ||
|
Insulet Corporation
PODD
|
75 M | $ 219.51 | 1.62 % | $ 15.4 B | ||
|
Quanterix Corporation
QTRX
|
13.6 M | $ 4.02 | 1.52 % | $ 171 M | ||
|
Electromed
ELMD
|
2.67 M | $ 24.79 | 0.53 % | $ 210 M | ||
|
Sintx Technologies
SINT
|
382 K | $ 2.5 | -2.34 % | $ 6.93 M | ||
|
Cytosorbents Corporation
CTSO
|
3.34 M | $ 0.61 | -9.18 % | $ 33.2 M | ||
|
Aethlon Medical
AEMD
|
535 K | $ 2.37 | 2.16 % | $ 3.7 M | ||
|
BIOLASE
BIOL
|
6.06 M | - | -13.19 % | $ 166 K | ||
|
LivaNova PLC
LIVN
|
97.2 M | $ 64.75 | 2.29 % | $ 3.53 B | ||
|
InspireMD
NSPR
|
1.26 M | $ 1.74 | -0.57 % | $ 112 M | ||
|
Sensus Healthcare
SRTS
|
1.2 M | $ 4.13 | -2.13 % | $ 67.4 M | ||
|
AdaptHealth Corp.
AHCO
|
352 M | $ 11.58 | 1.67 % | $ 1.56 B |